A Phase 3 Multi-center, Open-Label Study to Evaluate Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)

Trial Profile

A Phase 3 Multi-center, Open-Label Study to Evaluate Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Jun 2017

At a glance

  • Drugs Abatacept (Primary)
  • Indications Juvenile rheumatoid arthritis
  • Focus Pharmacokinetics; Registrational
  • Acronyms JIA-2
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 22 Jun 2017 Planned End Date changed from 1 Mar 2019 to 29 Dec 2023.
    • 17 Jun 2017 Results (n=173) of 6-17 year age cohort assessing effect of subcutaneous abatacept on patient reported outcomes presented at the 18th Annual Congress of the European League Against Rheumatism.
    • 08 Jun 2017 Results published in a Bristol-Myers Squibb media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top